Acadia Pharmaceuticals (ACAD) Inventory Average (2016 - 2026)

Acadia Pharmaceuticals' Inventory Average history runs 11 years deep, the most recent figure standing at $33.1 million for Q1 2026.

• On a quarterly basis, Inventory Average rose 47.55% year-over-year to $33.1 million in Q1 2026; TTM through Mar 2026 was $33.1 million, a 47.55% increase from a year earlier, with the FY2025 full-year figure at $28.3 million, down 1.99% from the prior year.
• Inventory Average rose to $33.1 million in Q1 2026 per ACAD's latest filing, from $31.9 million in the prior quarter.
• Across five years, Inventory Average topped out at $66.7 million in Q2 2024 and bottomed at $6.1 million in Q3 2022.
• The 5-year median for Inventory Average is $24.5 million (2025), against an average of $26.3 million.
• Across the five-year window, Inventory Average soared 772.64% in 2024 and slumped 63.23% in 2025, its largest moves.
• Year by year, Inventory Average stood at $6.2 million in 2022, then soared by 353.42% to $28.3 million in 2023, then soared by 46.66% to $41.5 million in 2024, then decreased by 23.16% to $31.9 million in 2025, then grew by 3.88% to $33.1 million in 2026.
• Per Business Quant, the three latest ACAD Inventory Average figures stand at $33.1 million (Q1 2026), $31.9 million (Q4 2025), and $27.6 million (Q3 2025).